ArticleJournal of nanobiotechnology2026
Restoration of macrophage mitochondrial dynamics and trafficking with enzymatic magnesium-manganese layered double hydroxide for osteoporotic therapy.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Macrophages play pivotal roles at the interface of immune regulation and bone metabolism and frequently exhibit a proinflammatory phenotype that contributes to the osteoporotic microenvironment. We found that dysfunctional macrophages in the osteoporotic niche transferred injured mitochondria to osteoblasts, which was associated with increased cellular senescence and impaired osteogenic function. This detrimental mitochondrial transfer was associated with abnormal accumulation of succinate dehydrogenase (SDH), contributing to maintenance of the proinflammatory phenotype and mitochondrial injury. On the basis of this mechanism, a folate (FA)-modified magnesium-manganese layered double hydroxide (MgMn-LDH) loaded with the SDH inhibitor dimethyl malonate (DMM) was designed to modulate proinflammatory macrophages. This system promoted BNIP3-LC3B-associated mitophagy, which was accompanied by improved mitochondrial quality control, mitochondrial dynamics and mitochondrial transfer capacity. The functional mitochondrial transfer from treated macrophages to neighboring osteoblasts was associated with enhanced osteogenic activity under osteoporotic conditions. Furthermore, MgMn-LDH/DMM@FA treatment significantly ameliorated bone loss and improved bone microarchitecture in ovariectomized mice. Collectively, these findings suggest that mitigating mitochondrial injury and enhancing functional mitochondrial transfer in proinflammatory macrophages may represent a promising strategy for alleviating osteoporosis. An enzyme-active MgMn-LDH-based delivery system provides a potential therapeutic platform for osteoporosis intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.